Navigation Links
Life Science Alley: R&D Makes German Medical Technologies Top in Europe
Date:12/8/2008

BERLIN, December 8 /PRNewswire/ -- Germany is Europe's largest market for medical devices. Total industry revenue in 2007 amounted to EUR 17.3 billion - a nearly 7 percent increase on 2006 figures. Investors looking to enter the German and European markets can learn about Germany at Life Science Alley, the largest convention of life science industry professionals in the American Midwest. The conference takes place December 10, 2008 in Minneapolis, Minnesota.

Germany's research landscape is making its medical technologies some of the most renowned and trusted worldwide. The country's advanced R&D network ensures that both patients and practitioners have access to the latest medical technologies.

Currently German medical technology companies spend about 9 percent of sales revenue on R&D. As a result, products under three years old account for 32 percent of industry revenue in Germany. Furthermore, Germany is number two in the world in patent applications in medical technologies.

Demographic developments suggest that Germany will remain strong in medical technologies in coming years. By 2015 it is expected that nearly one fifth of Germany's population will be over age 65, increasing the need for advanced medical technologies and health care.

Existing clusters of manufacturers, research institutes, and clinics allow companies of all sizes the chance to use Germany's investment conditions to maximize earnings quickly and efficiently. The availability of investment incentives as well as R&D and labor incentives also makes the country an attractive investment location.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. It can be found at booth 301 at Life Science Alley.

    Media Contact:
    Eva Henkel
    Phone: +49-30-200099-173
    Fax:   +49-30-200099-111
    Email: henkel@invest-in-germany.com



'/>"/>
SOURCE Invest in Germany GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):